Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2007;38:2373-2375
Published online before print June 21, 2007, doi: 10.1161/STROKEAHA.106.480038
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
38/8/2373    most recent
STROKEAHA.106.480038v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Katayama, Y.
Right arrow Articles by Yoshimine, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Katayama, Y.
Right arrow Articles by Yoshimine, T.
Related Collections
Right arrow Other Stroke Treatment - Medical
Right arrow Acute Stroke Syndromes
Right arrow Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage

(Stroke. 2007;38:2373.)
© 2007 American Heart Association, Inc.


Research Letters

A Randomized Controlled Trial of Hydrocortisone Against Hyponatremia in Patients With Aneurysmal Subarachnoid Hemorrhage

Yoichi Katayama, MD, PhD; Jo Haraoka, MD, PhD; Hidehiro Hirabayashi, MD, PhD; Tatsuro Kawamata, MD, PhD; Keiji Kawamoto, MD, PhD; Takao Kitahara, MD, PhD; Jun Kojima, PhD; Toshihiko Kuroiwa, MD, PhD; Tatsuro Mori, MD, PhD; Nobuhiro Moro, MD, PhD; Izumi Nagata, MD, PhD; Akira Ogawa, MD, PhD; Kikuo Ohno, MD, PhD; Yoshikatsu Seiki, MD, PhD; Yoshiaki Shiokawa, MD, PhD; Akira Teramoto, MD, PhD; Teiji Tominaga, MD, PhD Toshiki Yoshimine, MD, PhD

From the Department of Neurological Surgery (Y.K., T. Kawamata, J.K., T.M., N.M.), Nihon University School of Medicine; the Department of Neurosurgery (J.H.), Tokyo Medical University; the Department of Neurosurgery (H.H.), Nara Medical University; the Department of Neurosurgery (K.K.), Kansai Medical University; the Department of Emergency and Critical Care Medicine (T. Kitahara), Kitasato University School of Medicine; the Department of Neurosurgery (T. Kuroiwa), Osaka Medical College; the Department of Neurosurgery (I.N.), Nagasaki University School of Medicine; the Department of Neurosurgery (A.O.), Iwate Medical University; the Department of Neurosurgery (K.O.), Graduate School of Medicine, Tokyo Medical and Dental University; the Department of Neurosurgery (Y. Seiki), Toho University School of Medicine; the Department of Neurosurgery (Y. Shiokawa), Kyorin University School of Medicine, the Department of Neurosurgery (A.T.), Nippon Medical School; the Division of Neurosurgery (T.T.), Department of Neuroscience and Sensory Organs, Tohoku University Graduate School of Medicine; and the Department of Neurosurgery (T.Y.), Osaka University Medical School, Japan.

Correspondence to Yoichi Katayama, MD, PhD, Department of Neurological Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo 173-8610, Japan. E-mail JDW06164{at}nifty.ne.jp

Abstract

Background and Purpose— Hyponatremia is common after aneurysmal subarachnoid hemorrhage (SAH). It is caused by natriuresis, which induces osmotic diuresis and decreases blood volume, contributing to symptomatic cerebral vasospasm (SCV). Hypervolemic therapy to prevent SCV will not be efficient under this condition. We conducted a randomized controlled trial to assess the efficacy of hydrocortisone, which promotes sodium retention in the kidneys.

Methods— Seventy-one SAH patients were randomly assigned after surgery to treatment with either a placebo (n=36) or 1200 mg/d of hydrocortisone (n=35) for 10 days and tapered thereafter. Both groups underwent hypervolemic therapy. The primary end point was the prevention of hyponatremia.

Results— Hydrocortisone prevented excess sodium excretion (P=0.04) and urine volume (P=0.04). Hydrocortisone maintained the targeted serum sodium level throughout the 14 days (P<0.001), and achieved the management protocol with lower sodium and fluid (P=0.007) supplementation. Hydrocortisone kept the normal plasma osmolarity (P<0.001). SCV occurred in 9 patients (25%) in the placebo group and in 5 (14%) in the hydrocortisone group. No significant difference in the overall outcome was observed between the 2 groups.

Conclusions— Hydrocortisone overcame excess natriuresis and prevented hyponatremia. Although there was no difference in outcome, hydrocortisone supported efficient hypervolemic therapy.


Key Words: hydrocortisone • hyponatremia • multicenter studies • randomized controlled trials • subarachnoid hemorrhage




This article has been cited by other articles:


Home page
StrokeHome page
G. K. C. Wong and W. S. Poon
Risk of High Dose Hydrocortisone in Patients With Aneurysmal Subarachnoid Hemorrhage
Stroke, January 1, 2008; 39(1): e12 - e12.
[Full Text] [PDF]